Aether Biomachines, Inc.

Aether Biomachines, Inc. is a US-based company specializing in advanced enzyme engineering, utilizing a proprietary platform for creating innovative biocatalysts that enhance manufacturing processes across various industries. Founded in 2017 in Menlo Park, US, Aether Biomachines, Inc. focuses on enzyme engineering and has successfully raised USD 49.

000 mn in Series A funding on August 16, 2023, from investors including Natural Capital and Unless. Aether Bio specializes in advanced enzyme engineering, employing a proprietary platform that allows for the rapid and efficient creation of biocatalysts. Their offerings include custom-designed enzymes, which facilitate the production of complex and novel products at significantly reduced costs. By mapping trillions of enzymes, Aether provides a searchable index for clients in sectors such as pharmaceuticals, biofuels, and specialty chemicals, addressing challenges in scalability and efficiency.

Their global client base spans North America, Europe, and Asia. Aether Bio generates revenue primarily through strategic partnerships and direct business-to-business transactions, providing custom enzyme design services. Clients engage Aether to develop specific biocatalysts tailored to their needs, with pricing based on project agreements or retainers for ongoing support. Revenue structures are determined by the complexity of the enzyme engineering required.

In December 2025, Aether Biomachines, Inc. raised USD 15 million in venture funding led by Tribe Capital, with participation from Henkel Corporation Master Retirement Trust, Resilience Reserve, Shrug Capital, 4DX Ventures, Radicle Impact Partners, Natural Capital and Unless also participated in the round.